Questions and responses 45th Parliament, 1st session May 26, 2025, to present

With regard to the recipients of funding from the Strategic Science Fund, since 2019: (a) what are the details of each company that received funding from the fund, including, (i) the name of the recipient, (ii) the amount of funding received to date, (iii) the total amount of funding awarded, (iv) a description of the project; (b) what are the stated details in their application, including the (i) proposed objectives that were clearly linked to federal priorities and responsibilities, (ii) listed value added to existing federal government investments, (iii) reason why no alternative federal sources of funding could be accessed by the recipient, (iv) previous federal funding sources that the applicant attempted to access prior to their application, (v) listed efforts made by the applicant towards equity, diversity and inclusion, (vi) listed performance indicators suggested by the applicant to measure their impact; (c) when the department is monitoring the performance indicators of the funding recipients, (i) how does the department determine whether the recipient is meeting their listed performance indicators, (ii) what efforts have been made by the department to monitor these indicators; and (d) what intellectual property or pre-commercial science has been developed as part of the funding?

With regard to the Imagining Canada's Future Ideas Lab: (a) how much funding was provided to recipients, broken down by year since 2021; and (b) has the government conducted any research or does it have any statistics on the economic impact resulting from the funding provided to date, and, if so, what are the related statistics and the details of the research?

With regard to the government's commitment to undertake research providing insights into the reasons why people seek medical assistance in dying and the views and experiences of medical assistance in dying among key populations: (a) what studies, surveys, or research projects have been initiated, funded, commissioned, or completed by the government since January 1, 2024, on the reasons for medical assistance in dying requests; (b) for each study, survey, or research project in (a), what were the results or findings; (c) what variables related to social determinants of health and structural vulnerability were included in each study, including, but not limited to, income insecurity, housing insecurity, disability supports, access to mental health care, and social isolation; (d) what research or tools have been developed to detect or assess coercion, inducement, or "choice under constraint" in medical assistance in dying requests, including for Track 2 cases; and (e) what findings exist on the relationship between medical assistance in dying requests and socio-economic deprivation or unmet social needs?

With regard to Fisheries and Oceans Canada: (a) between March 15, 2026, and April 15, 2026, how many Fisheries and Oceans Canada mandated, authorized or chartered flights were flown over ice flows in Northwest Atlantic Fisheries Organization areas 2GHJ, 3K and 4RST; (b) what were the date and flight path of each such flight; (c) what observations of seals were made on each flight, including the species, numbers and locations; and (d) why is the data in (c) no longer being proactively provided to the sealing industry?

With regard to the government’s announcement in budget 2024 that they will create a new “capstone research funding organization”: (a) what will be the purpose of this organization; (b) how much money has been allocated to, or is projected to be required by, this organization to date and over each of the next five fiscal years; (c) what specific gaps, deficiencies, or coordination challenges in the current federal research support system is this new capstone organization intending to address; (d) what is expected to be achieved by the organization in the (i) short, (ii) medium, (iii) long, term; (e) how will capstone fit in organizationally with the (i) Canadian Institutes of Health Research, (ii) Natural Sciences and Engineering Research Council of Canada, (iii) Social Sciences and Humanities Research Council; (f) will the new capstone organization have any funding authority or influence over any of the entities in (e), and, if so, what are the details; (g) how will the government avoid duplication between the work of capstone and the other entities in (e); (h) what impact, if any, will the establishment and funding of capstone have on the funding of the other entities in (e); (i) what metrics will be used to assess the impact of the new capstone organization, and whether or not the government is receiving value for its money; (j) how often will the assessments in (i) take place, and how will the results be made public; (k) what will be the composition of the board, or other governing body of the capstone, and how much will they be paid; and (l) on what date is capstone expected to be fully operational?

With regard to meetings held by the Strategic Science Fund's steering committee in which a declaration, conflict, potential perception of conflict, abstention or recusal was noted in the meeting minutes, from December 1, 2022, to June 11, 2025: what are the details of each instance noted in the meeting minutes, broken down by director, including (i) the decision in question, (ii) the amount of funding tied to the decision, (iii) the name of the entity receiving funding related to the decision, (iv) the name of the board member for whom a declaration, conflict, potential perception of conflict, abstention or recusal was noted, (v) the reason for which the declaration, conflict, potential perception of conflict, abstention or recusal was divulged by the board member, (vi) whether the board member held a private interest in the decision?

With regard to Health Canada, Public Health Agency of Canada and National Advisory Committee on Immunization expenditures between 2020 and 2023: (a) which projects and departments researched the safety of the COVID-19 vaccines and how much did each project cost, broken down by (i) project name, (ii) department name, (iii) start date, (iv) completion date, (v) cost; (b) which projects and departments researched manufacturers' COVID-19 vaccine applications and how much did each project cost, broken down by (i) vaccine name, (ii) project name, (iii) department name, (iv) start date, (v) completion date, (vi) cost; (c) which projects and departments informed Canadians and specialists about the adverse events associated with the COVID-19 vaccines, broken down by (i) project name, (ii) department name, (iii) adverse event, (iv) start date, (v) completion date, (vi) date Canadians were informed about the adverse event, (vii) cost; and (d) which projects and departments researched vaccine hesitancy and how much did each project cost, broken down by (i) project name, (ii) department name, (iii) start date, (iv) completion date, (v) cost?

With regard to the National Research Council of Canada's Industrial Research Assistance Program funding, since January 1, 2016: (a) how many firms in the program's database have left Canada; (b) how many different firms received financial support, broken down by year; (c) of the recipients in (b), how many have since either left Canada or been acquired by foreign owners; and (d) for each National Research Council of Canada Industrial Research Assistance Program recipient firm that has left Canada or been acquired by foreign owners, what are the details, including (i) the recipient, (ii) the amount of original funding, (iii) the project description or purpose of the funding, (iv) how much of their contribution agreement funding has been paid back to date (total dollars and percentage of total obligations)?